LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

102.35 1

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

100.15

Max

106.2

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	13.501 49.888
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 368M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+7.47% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	49M 19B
Iepriekšējā atvēršanas cena	101.35
Iepriekšējā slēgšanas cena	102.35

Ziņu noskaņojums

By Acuity

66%

34%

289 / 344 Rangs Healthcare

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. jūn. 19:20 UTC

Galvenie tirgus virzītāji

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026. g. 5. jūn. 21:27 UTC

Peļņas

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 20:20 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026. g. 5. jūn. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026. g. 5. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Hog Futures Tumble to Close Week -- Market Talk

2026. g. 5. jūn. 19:10 UTC

Tirgus saruna

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026. g. 5. jūn. 19:03 UTC

Tirgus saruna

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026. g. 5. jūn. 18:59 UTC

Tirgus saruna

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026. g. 5. jūn. 18:47 UTC

Tirgus saruna

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026. g. 5. jūn. 18:34 UTC

Tirgus saruna

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026. g. 5. jūn. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026. g. 5. jūn. 17:50 UTC

Peļņas

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026. g. 5. jūn. 17:27 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026. g. 5. jūn. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 15:44 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 15:26 UTC

Tirgus saruna

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

2026. g. 5. jūn. 15:25 UTC

Peļņas

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

2026. g. 5. jūn. 15:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 5. jūn. 15:16 UTC

Tirgus saruna

Zcash Tumbles After Exploit Found -- Market Talk

2026. g. 5. jūn. 15:09 UTC

Tirgus saruna

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

2026. g. 5. jūn. 15:07 UTC

Tirgus saruna

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

2026. g. 5. jūn. 15:05 UTC

Tirgus saruna

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

7.47% augšup

Prognoze 12 mēnešiem

Vidējais 108.8 USD 7.47%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 18 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

289 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation